Three Stocks To Keep An Eye On The First Week Of June 2019

As the US Government and China are set to escalate the trade war even further, this is going to be another rough week for the market. But, amidst all the struggle between the two countries, there are still great stocks to check, which shouldn’t be victims of the current situation. Let’s take a look at these three stocks with the help of news on investing.

Three Stocks To Keep An Eye On – The First Week Of June 2019

  • (CRM) is one of the most recognizable names in cloud computing. This company offers cloud-based service to corporate clients and as it stands, it’s one of the best options at the moment. The company will report its 2019 earnings on June 4. The analysts expect $0.61 a share profit on sales of $3.56 billion. At the beginning of June 2019, the stock traded at $151.41 per share. The sales were predicted to be $3.67 to $3.67 billion in the first half of 2019.

  • CVS Health (CVS)

At the beginning of May 2019, CVS Health boosted its profit outlook. Yet, this healthy profit failed to encourage investors as the stock lost another 20% in its value. Despite all of this, analysts predict that CVS management should help alleviate the uncertainty about shares. The great thing is that CVS Health made a $69-billion merger with Aetna, which is one of the largest health care companies. This should help CVS Health to regain revenue and flourish in 2019.

  • Beyond Meat (BYND)

Beyond Meat is a heaven for the vegans. This company is all about making plant-based meat substitute products that saw a major recognition during the past couple of years. At the beginning of June, the stock closed at $104.12 and it’s sort of a tease for the investors since the IPO at the beginning of May. Beyond Meat also developed three new plant-based products to stay in line with the most popular meat categories globally. Analysts expect a loss of $0.16 per share, with sales surging to $31.5 million.

Disclaimer: The information on this site is provided for discussion purposes only, and should not be misconstrued as investment advice. Under no circumstances does this information represent a recommendation to buy or sell securities.